| 1 |
Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung and Heart-Lung Transplant Report-2017[J]. J Heart Lung Transplant, 2017，36(10): 1037-1079
|
| 2 |
Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients[J]. J Heart Lung Transplant, 2010，29(8):914-956.
|
| 3 |
Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation[J]. J Heart Lung Transplant, 2005，24(9):1297-1304.
|
| 4 |
郑哲，黄洁，杨立猛，等. 巴利昔单抗联合三联免疫抑制方案预防心脏移植后急性排斥反应[J]. 中华器官移植杂志，2012，33(5):272-274.
|
| 5 |
Delgado DH, Miriuka SG, Cusimano RJ, et al. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction[J]. J Heart Lung Transplant, 2005，24(2):166-169.
|
| 6 |
Haba T, Uchida K, Katayama A, et al. Pharmacokinetics and pharmacodynamics of chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japannese and Non-Japanese patients[J]．Transplant Proc, 2001，33(7-8):3174-3175.
|
| 7 |
黄洁，郑哲，胡盛寿，等. 心脏移植后采用他克莫司替代环孢素A治疗的体会[J]. 中华器官移植杂志，2008，29(5):298-300.
|
| 8 |
刘冰洋，柳青，郑哲，等. 受者CYP3A5基因多态性对心脏移植术后血他克莫司浓度的影响[J]. 中华器官移植杂志，2017，38(5):262-266
|
| 9 |
Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients[J]. J Heart Lung Transplant, 2005，24(5):517-525.
|
| 10 |
Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial[J]. Circulation, 2004，110(17):2694-2700.
|
| 11 |
尹栋，黄洁，丰雷，等. 心脏移植术后慢性肾功能不全患者应用西罗莫司的经验[J]. 中华心血管病杂志，2012，40(2):136-140
|
| 12 |
Delgado Jiménez J, Almenar Bonet L, Paniagua Martín MJ, et al. Influence of steroid dosage, withdrawal, and reinstatement on survival after heart transplantation: results from the RESTCO study[J]. Transplant Proc, 2012，44(9):2679-2681.
|
| 13 |
黄洁. 心脏移植免疫抑制诱导和维持治疗[J/CD]. 中华移植杂志：电子版，2018，12(2):49-54.
|
| 14 |
黄洁，杨跃进，杨伟宪，等. 心内膜心肌活检监测移植心脏排斥反应——附213例次心内膜活检结果分析[J]. 中华器官移植杂志，2007，28(11):672-674.
|
| 15 |
Elliott P, Arbustini E. The role of endomyocardial biopsy in the management of cardiovascular disease: a commentary on joint AHA/ACC/ESC guidelines[J]. Heart, 2009，95(9):759-760.
|
| 16 |
Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation[J]. J Heart Transplant, 1990，9(6):587-593.
|
| 17 |
Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection[J]. J Heart Lung Transplant, 2005，24(11):1710-1720.
|
| 18 |
Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 2013，32(12):1147-1162.
|
| 19 |
Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association[J]. Circulation, 2015，131(18):1608-1639.
|